Patient Philosophy

Liana, diagnosed with hATTR amyloidosis
and her daughter Gabriella (Brazil)

Approach to Access and Affordability Fact Sheet

Download our 2022 Approach to Access and Affordability Fact Sheet to see statistics that illustrate our progress against these principles.


patients on Alnylam commercial therapies worldwide

U.S. lives with confirmed access to one of our four products

markets where patients have received access to Alnylam therapies

Alnylam’s Patient Access Philosophy Principles

Above All, We Put Patients First:


  • We recognize that access and affordability mean more than insurance coverage and reimbursement.
  • We commit to listen and learn from patients, caregivers, healthcare providers, payers, and regulatory bodies to develop and advocate for sustainable solutions that improve access and outcomes.
  • We strive to provide resources that are relevant to the patient and their treatment team and help make decisions that are best for them.
  • We believe proactive steps for better access today will advance innovation that will enable us to help even more people in the future.

We Provide Value that Transcends Borders


  • We commit to responsible, evidence-based pricing of our products to reflect the value delivered to patients, caregivers and society.
  • We remain committed to growth through continuous innovation, not arbitrary price increases, and expanding our geographic reach to create sustainable access pathways for patients around the world.
  • We view patient access as a responsibility that requires innovative, sustainable solutions developed in collaboration with all those involved in the delivery of care.

We Are Proactive and Accountable


  • We recognize that no single solution can meet all challenges.
  • We always act with medical and scientific excellence and integrity.
  • We advocate for policies that promote innovation and value communication, so that eligible patients can access our medicines.
  • We measure and report out on our progress to help patients access our therapies.
  • We continue to innovate, acting with urgency to minimize the time it takes to get approved therapies to patients.

Learn More About How We Measure Our Progress Against Our Patient Access Principles:


2022 Approach to Access and Affordability Fact Sheet


Corporate Social Responsibility Report 2022


Additional Information

Alnylam Assist®

Alnylam Assist®

Alnylam Assist® offers you a number of personalized services throughout your treatment with an Alnylam product.


Alnylam Act®

Alnylam Act® provides no-charge, independent genetic testing and counseling to individuals in the U.S. and Canada who may have hATTR amyloidosis, acute hepatic porphyria, or primary hyperoxaluria type 1.

Visit Site ›


Receive news and updates on the work at Alnylam that affects you most.
Custom Body Class